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Abstract
Background: In recent years, most insurance plans eliminated cost-sharing for breast cancer 
screening, recommended screening intervals changed, and newer modalities—digital 
mammography and breast tomosynthesis—became more widely available. The objectives of this 
study are to examine how these changes affected utilization, frequency, and costs of breast cancer 
screening among commercially insured women, and to understand factors associated with 
utilization and frequency of screening.
Methods: This study used commercial insurance claims data for women aged 50 to 64 years 
continuously enrolled in commercial insurance plans during 2012–2016.
Results: Of the 685,737 eligible women, 20% were not screened, 40% received annual 
screening, 24% received biennial screening, and 16% were screened less frequently than 
recommended during the time period examined. Sociodemographic factors such as age <60 years, 
rurality, and fee-for-service insurance were associated with low screening utilization. Patients who 
received annual screening incurred approximately 1.78 times higher costs as compared to those 
who received biennial screening during the study period. Digital mammography was the most 
costly and commonly used modality along with computer-aided detection.
Conclusions: Evidence-based interventions to promote screening among women who are 
screened less frequently are needed along with interventions to move toward biennial screening 
rather than annual screening. Increasing provider awareness regarding breast cancer screening 
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rates and frequency among various sociodemographic groups is essential to guide provider 
recommendations and shared decision making. The results of this study can guide targeted public 
health interventions to reduce barriers to screening, and can also serve as inputs for economic 
analyses of screening interventions and programs.
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Introduction
Breast cancer screening with mammography is recommended to reduce breast cancer 
mortality for women aged 50–74 years.1 Beginning in 2011, many private health insurers 
were required to cover mammography screening without cost-sharing.2 Little evidence exists 
about how these changes affected screening utilization among commercially insured women.
3,4
 Analysis of the 2015 National Health Interview Survey (NHIS) indicated that 76.7% of 
privately insured women aged 50–74 received a mammogram within the past 2 years.5 
Although cancer screening prevalence is commonly based on self-reported data such as the 
NHIS, these estimates may be overreported.6 The evidence is scant on the sociodemographic 
factors associated with breast cancer screening utilization and frequency among 
commercially insured women, after elimination of financial barriers.
Consistent with its 2009 recommendation for women aged 50–74 years, in the 2016 update, 
the US Preventive Services Task Force (USPSTF) reaffirmed its position that women in this 
age group who have an average risk of developing breast cancer should undergo routine 
biennial screening mammography.7 However, there were different guidelines from other 
medical organizations such as the American Cancer Society (updated to biennial screening 
for women aged 55 years and above in October, 20158) and the American College of 
Radiology (annual screening for women aged 50 to 64 years).9,10 Compared to biennial 
screening, annual screening has additional costs and may not provide the best balance of 
harms and benefits for many women.7 Previous research among commercially insured 
women has not examined the rate of annual screening and its associated factors and the 
additional cost of annual screening compared to biennial screening.
Since early 2000, digital mammography with or without computer-aided detection (CAD) 
has become the most commonly used breast cancer screening modality in the US.11 While 
film mammography had been the mainstay prior to 2000, today nearly 90% of all 
mammography screenings in the United States are digital.12 Digital mammography costs 
more,13,14 may offer no significant advantage in older women without dense breasts,15 and 
may not be cost-effective in women aged 50 years and older.16 The utilization of CAD and 
digital breast tomo-synthesis (DBT) is rising because it can decrease recall rates among 
women<50 years with dense breasts.17 However, the benefits of these new, high-cost 
modalities for screening women aged 50 to 64 years without dense breasts are 
uncertain7,18,19 and the evidence regarding their cost-effectiveness is limited due to lack of 
precise cost estimates.20,21 An understanding of the utilization and costs of various breast 
cancer screening modalities can inform efforts to identify screening strategies that provide 
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the best value. Previous research has not examined the proportion of privately insured 
women who still pay some out-of-pocket (OOP) costs for each screening modality and the 
mean OOP costs paid by these women using claims data.
This study of breast cancer screening among commercially insured women aged 50 to 64 
years during 2012–2016 has four objectives: 1) to examine the utilization and frequency of 
mammography after elimination of cost-sharing in many private insurance plans, 2) to 
examine sociodemographic factors associated with utilization and frequency, 3) to estimate 
the utilization, direct medical costs, and OOP costs of various screening modalities by type 
of insurance plan, and 4) to estimate aggregate costs by screening frequency and the cost-
savings associated with biennial screening compared to annual screening.
Materials and Methods
Data source
Outpatient claims data from January 1, 2011 to December 31, 2016 were used for this study, 
from the IBM Watson Health MarketScan Treatment Pathways® 100% data file, derived 
from the Truven Health MarketScan Commercial Claims and Encounters database. The 
MarketScan Commercial Claims and Encounters database contains person-level enrollment 
information linked to fully paid and adjudicated outpatient medical care claims for nearly 
43.6 million individuals annually who are covered by employer-sponsored group insurance.
22
Population Selection
The study population included all women with an outpatient claim continuously enrolled 
from January 1, 2011 to December 31, 2016 aged 50 to 64 years. Data from 2011 were used 
as a ‘look back’ period to exclude women with a diagnosis of breast cancer, breast 
involvement due to any disease condition, breast signs or symptoms such as lump, pain, 
breast inversion, or nipple discharge and lastly, women with a mastectomy. The look back 
period in this study is defined as the period between January 1, 2011 and the index date. The 
index date for those women who got a screening mammography is the date of the first 
screening whereas for those who did not get screened from 2012–2016, the index date is 
December 31, 2016. Diagnosis and procedure codes for screening modalities and exclusion 
criteria are presented in the Appendix. Since ICD-10 codes were adopted in October 2015, 
both ICD-9 and ICD-10 diagnosis codes were used for identifying exclusion criteria.23 
Women with capitated insurance plans and missing insurance plan information were 
excluded since the utilization and cost estimates for capitated plans are not accurately 
captured in MarketScan data. This study used de-identified patient records and did not 
involve the collection, use, or transmittal of individually identifiable data, therefore, 
Institutional Review Board approval was not required.
Data Analysis
This study was a retrospective observational cohort analysis utilizing the MarketScan 
Treatment Pathways (Truven Health Analytics, Inc., Ann Arbor, MI), a web-based data 
analysis tool. The tool was used to estimate the breast cancer screening utilization, 
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frequency and costs. In this study, annual screening was defined as average screening 
interval <1.5 years. Biennial screening was defined as average screening interval ≥1.5 years, 
and ≤2.5 years. Infrequent screening was defined as average screening interval greater than 
2.5 years.
The association between sociodemographic factors and utilization and frequency of breast 
cancer screening was first examined using bivariate analysis. The variables significant in the 
bivariate analyses were included in a multivariate logistic regression to estimate the odds 
ratios for receiving at least one screening mammogram during 2012–2016. Next, the 
relationship between demographic factors and screening frequency was examined using 
multinomial logistic regression. Screening frequency was categorized as 1) annual 
screening, 2) biennial screening, 3) infrequent screening (screening interval greater than 2.5 
years) and 4) no screening. No screening was used as the referent group for the multinomial 
regression.
The sociodemographic factors included in the analyses were age, geographic region, 
residence in a metropolitan statistical area as defined by U.S. Office of Management and 
Budget,24 relationship to insured employee (self or spouse), and type of insurance plan. Age 
was categorized as women aged 50–54, 55–59, and 60–64 years. Health insurance plans 
were categorized as 1) fee-for-service (FFS) including comprehensive plans, 2) non-
capitated managed care plans including exclusive provider organization, non-capitated point 
of service and preferred provider organization plans, and 3) high deductible plans including 
consumer directed health plans (CDHP) and high-deductible health plans (HDHP).
The direct medical cost and OOP cost for each screening modality by type of insurance were 
estimated by aggregating claims for the same procedure on the same service date for each 
enrollee. The direct medical cost of a procedure represents the amount eligible for payment 
after applying pricing guidelines such as fee schedules and discounts, and including 
deductibles, copayments, and coordination of benefits. The OOP cost was calculated by 
summing the copayment, coinsurance, and deductible paid by the patient. The mean OOP 
costs are computed only for those women who had a non-zero OOP cost. The costs reported 
are point-of-care costs. Costs related to harm of breast cancer screening were not captured in 
the analysis.
Total cost of all screening modalities per person was obtained by adding costs for all 
screening modalities received by a woman during the study period. Total costs by screening 
frequency were computed as a product of the number of women receiving annual, biennial, 
or infrequent screening and total cost of all screening modalities per person. Total costs for 
the entire sample were computed as a product of the number of women receiving any 
screening during the study period and total cost of all screening modalities per person. Costs 
for each year were converted to 2017$ using the Personal Health Care Expenditure (PHCE) 
component of the National Health Expenditure Accounts from Centers for Medicare and 
Medicaid Services (CMS).25 Next, the weighted average of costs for all years in 2017$ was 
computed based on utilization by year. All statistical analyses were performed using Stata 
14.
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Results
The sample flow diagram along with the inclusion and exclusion criteria is presented in 
Figure 1. The total number of women who met the study selection criteria was 685,737.
Breast cancer screening utilization and frequency
Table 1 presents the sample characteristics. Table 2 presents sample characteristics by 
receipt of any screening and by frequency of screening. Sample characteristics are presented 
as row percentages i.e. the percentages in the rows add up to 100%. Table 2 also presents 
results of bivariate analysis wherein women receiving at least one screening were compared 
to women who received no screening and women receiving annual, biennial, infrequent and 
no screening were compared to each other. Of all the women eligible to receive breast cancer 
screening, 80.3% (550,533) had at least one screening mammogram in 2012–2016 whereas 
19.7% (135,204) received no screening. Women aged 50–54 years and 55–59 years, spouses 
of employees, residing in northeast region, in non-metropolitan areas, and enrolled in fee-
for-service plans less often received any screening mammogram during the study period 
compared to women aged 60–64 years residing in metropolitan areas in regions other than 
northeast and enrolled in commercial insurance plans other than fee-for-service, respectively.
There were 166,579 (24.3% of all eligible women) who were screened biennially; 273,949 
(40.0%) who were screened annually, and 110,005 (16.0%) who were screened at intervals 
greater than 2.5 years. Annual screening was more common among women aged 50 to 54 
and 55 to 59 compared to older women whereas infrequent screening was more common 
among women aged 60 to 64 years. Annual screening was more common among women 
enrolled in a consumer directed/high deductible health plan whereas infrequent screening 
and no screening was more common among women enrolled in fee-for-serve plans. Annual 
screening was more common among women residing in the South and biennial screening 
among women residing in the West. Differences in infrequent screening across regions were 
small. Annual screening was more common among employees whereas infrequent screening 
was more common among spouses of employees. All variables were significant in the 
bivariate analyses at P-value<0.01.
Factors associated with breast cancer screening utilization and frequency
Table 3 presents the odds ratios (OR) and 95% confidence intervals (CIs) from the logistic 
regression with receipt of at least one breast cancer screening during the study period as the 
dependent variable. Women aged 50–54 years (OR: 0.33, 95% CI: 0.32–0.34) and 55–59 
years (OR: 0.4 95% CI: 0.39–0.41 ) (comparison group: 60–64 years), residing in non-
metropolitan areas (OR: 1.3, 95% CI: 1.28–1.32) (comparison group: metropolitan areas), 
residing in the Northeast (OR: 0.59, 95% CI: 0.58–0.6) and Midwest region (OR: 0.88, 95% 
CI: 0.86–0.89) (comparison group: South), women enrolled in a fee-for-service plan, and 
spouses of insured employees (OR: 0.87, 95% CI: 0.86–0.88) (comparison group: employee) 
were significantly less likely to receive any breast cancer screening during the study period. 
Conversely, women enrolled in a non-capitated managed care plan (OR: 1.98, 95% CI: 1.94–
2.03) or high deductible plan (OR: 2.68, 95% CI: 2.6–2.76) (comparison group: fee-for-
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service) were significantly more likely to receive any breast cancer screening during the 
study period.
Table 3 also reports relative risk ratios (RR) from the multinomial logistic regression with 
screening frequency (annual screening, biennial screening, infrequent screening or no 
screening) as the dependent variable and no screening as the referent group. Relative to 
those who received no screening, women aged 50–54 years (RR: 0.33, 95% CI: 0.32–0.34) 
and 55–59 years (RR: 0.40, 95% CI: 0.39–0.41), spouses of insured employees (RR: 0.87, 
95% CI: 0.86–0.88), those residing in the Northeast (RR: 0.50, 95% CI: 0.50–0.51), West 
(RR: 0.89, 95% CI: 0.87–0.91) or Midwest (RR: 0.94, 95% CI: 0.92–0.95) region, and 
enrolled in fee-for-service plans were significantly less likely to receive annual screening.
Relative to those who received no screening, women aged 50–54 years (RR for biennial 
screening: 0.39, 95% CI: 0.38–0.40) (RR for infrequent screening: 0.12, 95% CI: 0.12–0.12) 
and 55–59 years (RR for biennial screening: 0.44, 95% CI: 0.43–0.45) (RR for infrequent 
screening: 0.21, 95% CI: 0.20–0.22), spouses of insured employees (RR for biennial 
screening: 0.91, 95% CI: 0.89–0.92) (RR for infrequent screening: Not statistically 
significant), those residing in the Northeast (RR: 0.54, 95% CI: 0.53–0.55) (RR for 
infrequent screening: 0.61, 95% CI: 0.60–0.63), or Midwest (RR for biennial screening: 
0.97, 95% CI: 0.95–0.99) (RR for infrequent screening: 0.97, 95% CI: 0.95–0.99) region, 
and enrolled in fee-for-service plans were significantly less likely to receive biennial 
screening and infrequent screening.
Utilization and cost of breast cancer screening modalities by type of insurance
The utilization and costs (direct medical and OOP) of screening modalities along with 
proportion of women with non-zero OOP costs by type of insurance plan are presented in 
Table 4. Utilization is defined as the percentage of women who received the screening 
modality at least once during the study period. Among women who received at least one 
screening mammogram between 2012 and 2016, 97.6% received digital, 19.7% received 
film, 96.3% received CAD and 14.0% received digital breast tomosynthesis (DBT) (Table 
4). Utilization of screening modalities varied by type of insurance plan. Compared to other 
types of insurance plans, fee-for-service plans had the lowest utilization for DBT and the 
highest utilization for film mammogram whereas high deductible plans had the highest 
utilization of DBT. There was little difference in utilization of digital mammography and 
CAD across groups.
Direct medical costs were $112.75 (95% CI: 111.97–113.54) for film mammography, 
$175.58 (95% CI: 175.18–175.97) for digital mammography, $28.42 (95% CI: 28.27–28.57) 
for CAD, and $31.83 (95% CI: 31.29–32.37) for DBT. The direct medical costs for 
screening modalities varied by type of insurance plan. Women enrolled in high deductible 
plans had the lowest mean direct medical costs for film and digital mammography and those 
enrolled in fee-for-service plans had the lowest mean costs for CAD and DBT.
Only 5.2% of the women receiving breast cancer screening had OOP costs. The presence of 
OOP costs varied by screening modality, 3.0% of those who received CAD, 3.2% of those 
who received film mammography, 3.5% of those who received digital mammography, and 
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7.8% of those who received DBT had any OOP costs. The mean OOP cost for women who 
had non-zero OOP costs was $48.76 (95% CI: 45.01–52.41) for film, $62.66 (95% CI: 
61.01–64.31) for digital, $10.79 (95% CI: 10.10–11.48) for CAD, and $40.52 (95% CI: 
38.79–42.24) for DBT. The mean OOP costs varied by type of insurance plan. Women 
enrolled in high deductible plans had the highest mean OOP costs for all screening 
modalities except film mammography. Those enrolled in non-capitated managed care plans 
had the lowest mean OOP costs for film and digital mammography whereas OOP costs for 
CAD and DBT were lowest among those enrolled in fee-for-service plans.
Additional costs for women who received annual screening in 2012–2016
Table 5 presents the mean total cost per person for screening and the mean total cost for the 
sample by screening frequency. Women who received annual screening had a mean total cost 
of $1411.23 (95% CI: 1407.35–1415.1) whereas women who received biennial screening 
had a mean total cost of $792.10 (95% CI: 789.13–795.07). Thus, women who received 
annual screening incurred approximately 1.78 times higher costs or an additional $619.13 
(95% CI: 618.22–620.33) as compared to those who received biennial screening during the 
study period. A total of 273,949 women who received annual screening during the study 
period had a total cost of $39 million whereas 166,579 women who received biennial 
screening during the study period had a total cost of $13 million.
Discussion
Summary of results
Among commercially insured women aged 50–64 years in 2012–2016, 64% received breast 
cancer screening with screening interval less than≤2.5 years. This is lower than the Healthy 
People 2020 biennial screening target of 81%.26 Despite elimination of financial barriers in 
many private plans, 20% eligible women still did not receive any screening during the study 
period and 16% received infrequent screening. Women aged 50 to 59 years, residing in non-
metropolitan areas, in the Northeast and Midwest regions, enrolled in fee-for-service plans, 
and spouses of insured employees were less likely to receive at least one breast cancer 
screening during the study period. While women aged 60 to 64 years had higher likelihood 
of receiving at least one screening mammogram, they were more likely to have longer than 
recommended interval between mammograms. Out of the women who received at least one 
screening mammogram during 2012–2016, 50% received annual screening. Compared to 
women who received no screening, women aged 60–64 years, insured employees, residing 
in the South, and enrolled in non-capitated managed care or high deductible health plans had 
higher rates of receiving annual screening. If annual screening was substituted by biennial 
screening in the study sample, it would result in per-person saving of $619 in direct medical 
costs.
Some evidence suggests that newer diagnostic modalities have uncertain benefits women 
aged 50 to 64 years. Prior studies have reported that for some women there may be no 
statistically significant differences in sensitivity and specificity of film mammography and 
the more costly digital mammography.13,15 Cole et al. (2014) reported that sensitivity and 
specificity of CAD is not significantly different from digital mammography.27 Lei et al. 
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(2014) reported that DBT has higher sensitivity (90% vs 89%) and specificity (79% vs 72%) 
than digital mammography based on a meta-analysis of seven studies.28 However, the value 
of CAD and DBT is uncertain in older women (>50 years of age) who do not have dense 
breasts.19 Despite uncertain benefits, the results of this study suggest high utilization of 
digital mammography (98%) and CAD (96%) in this sample of women aged 50–64 years. 
DBT utilization in this sample was 14%. The costs for mammography among commercially 
insured women in this study were higher than the amount allowed by Medicare in 2015 for 
all modalities except DBT. This included the commercial costs for film mammography 
($113 in 2017$ for commercial vs. $83 Medicare), digital mammography ($176 in 2017$ 
commercial vs. $135 Medicare), and CAD ($28 in 2017$ for commercial vs. $9 for 
Medicare). The commercial costs for DBT ($32 in 2017$ for commercial vs. $56 for 
Medicare) were lower than the amount allowed by Medicare.29
Only 5% of women had any OOP costs, 3% of those receiving film mammography and 
CAD, 4% of those receiving digital mammography, and 8% of those receiving DBT had 
OOP costs. This could be due to the novelty of DBT as a screening modality. Since 2011, 
patient cost-sharing for breast cancer screening was eliminated in many private plans. 
Results from this study suggest that during 2012–2016 the vast majority of women had no 
OOP cost for mammography.
Implications
Despite elimination of financial barriers in many plans, only 64% of commercially insured 
women received breast cancer screening biennially or more often. This finding underscores 
the importance of understanding and addressing non-financial barriers to screening. 
Evidence-based interventions recommended by the Community Preventive Services Task 
Force (CPSTF) can be implemented to increase screening use by increasing community 
demand for cancer screening, increasing provider delivery of screening services and 
reducing structural barriers to care.30 Some of these interventions include patient reminders 
which have been implemented to increase screening rates among insured populations.30 
CPSTF also provides recommendations for interventions to reduce structural barriers such as 
lack of transportation or inability to take time off work, and cultural and language barriers 
that can impede breast cancer screening, even among insured women.31 For those who still 
encounter cost barriers, reducing OOP costs is also recommended by the CPSTF to increase 
screening mammography use.32 Our study showed that women who were aged 50 to 59 
years, residing in non-metropolitan areas, spouses of employees, and enrolled in fee-for-
service plans may benefit from targeted interventions recommended by CPSTF. A recent 
report highlighted that despite similar incidence of breast cancer, rural areas experienced 
higher cancer deaths.33 Eliminating urban-rural disparities in screening may help reduce 
breast cancer deaths in non-metropolitan rural areas. CPSTF recommends several 
interventions to reduce structural barriers including offering services in alternative or non-
clinical settings such as mobile mammography vans in residential communities, eliminating 
or simplifying administrative procedures and providing services such as scheduling 
assistance, patient navigators, translation services, and transportation assistance.27 These 
interventions may help reduce rural disparities in utilization of breast cancer screening.
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Although breast cancer screening is known to reduce breast cancer mortality among women 
aged 50 to 64 years, there are certain harms associated with screening. These include false-
positive rates resulting in anxiety and distress, overdiagnoses associated with increased 
biopsies and other procedures, and pain and radiation exposure during the screening.34 
Nelson et al. reported that false-positive rates (61% vs 42%) and biopsies (7% vs 5%) were 
more common with annual screening than biennial screening.34 Thus, annual screening has 
higher costs and may not provide the best balance of benefits and harms compared to 
biennial screening.7,35 Among women who received at least one screening during the study 
period, 50% received annual screening. This finding indicates that despite USPSTF 
recommendations, annual screening continues as a routine practice. Barriers to adoption of 
USPSTF biennial screening recommendations by physicians may include patient 
preferences, concern about malpractice risk, preference for guidelines from American 
Cancer Society or other organizations, health system assessment of provider’s screening 
practices that use conflicting measurement criteria, and lack of time or training for shared 
decision making with patients.36 These barriers can be addressed by patient and physician 
education, use of decision tools for shared decision making, and better patient-physician 
communication in order to use limited healthcare resources in a way that provides the best 
value.37,38
The costs of mammography screening to the society are sensitive to the costs of screening 
modalities and the screening strategies used (biennial vs annual).35,39 Thus, it is important to 
understand the cost of each screening modality and the additional cost of annual screening 
as compared to biennial. Given the increased cost of newer modalities such as digital 
mammogram, CAD and DBT, understanding which women may benefit from them is 
important. In addition to the financial costs of screening modalities, understanding the harms 
of screening associated with newer modalities is also important. While combining 
tomosynthesis with mammography resulted in a decrease in recalls, it also resulted in an 
increase in biopsies compared with mammography alone.34
The results from this study highlight sub-populations that may benefit from evidence-based 
interventions to increase screening. These results also highlight the importance of physician 
awareness regarding screening rates and frequency among various sub-populations to guide 
shared decision making for screening. Lastly, the costs of screening modalities presented in 
this study can serve as inputs for future research on economic analyses of various alternative 
screening strategies, and interventions and programs to improve screening uptake.
Limitations
This study has some limitations. First, participating plans included in MarketScan may 
change over time, and as a result, conclusions about patterns of care, geographic differences, 
and changes over time may not be representative of the entire United States.40 Second, study 
outcomes were identified through administrative claims data, which are subject to data 
coding limitations and data entry errors. Third, the study was not designed to identify 
women for whom more frequent screening may be indicated (e.g. women at high risk for 
breast cancer including women with a family history of cancer, women recommended to 
have short interval follow up during the study period) or for whom newer modalities may be 
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appropriate (e.g. women with dense breasts). Fourth, the look-back period in this study to 
identify women who may have received a diagnostic screen is only one year since including 
extra years of look-back period may require increasing the number of years for which 
women need to be continuously enrolled. The shorter look-back period in this study may 
overestimate the prevalence of preventive screens. Fifth, this study did not control for 
comorbidities. Sixth, due to lack of data, racial and ethnic disparities in screening could not 
be analyzed. Lastly, the study is restricted to women aged 50 to 64 years so the results are 
not generalizable to younger women under 50 years of age.
Conclusions
In conclusion, this study provides valuable data on utilization, frequency, and cost of various 
breast cancer screening modalities among commercially insured women aged 50–64 years 
from 2012 to 2016. The results point to populations with lower likelihood of screening that 
may benefit from evidence-based interventions. The results of this study also draw attention 
to prevalence and additional costs of annual screening among women aged 50 to 64 years. 
Provider awareness of screening utilization and frequency among various sub-groups can 
guide appropriate provider recommendations and shared decision-making. The cost results 
presented in this study may serve as inputs for economic analyses of alternate screening 
strategies, programs, and interventions to improve screening uptake. The results of this study 
can guide targeted public health interventions such as small media, patient and provider 
reminders, and interventions to eliminate structural barriers27 in order to improve breast 
cancer screening rates.
Appendix
APPENDIX 1:
Diagnosis and Procedure Codes for Breast Cancer Screening and Breast Involvement
Description Code Type Code
Codes to identify breast cancer screening
Screening mammography, bilateral (2-view film study of each breast) CPT Procedure 77057
Screening mammography, producing direct digital image, bilateral, all views HCPS G0202
Add on code for computer-aided detection (computer algorithm analysis of digital 
image data for lesion detection) with further review for interpretation, with or 
without digitization of film radiographic images; screening mammography
CPT Procedure 77052
Add on code for screening digital breast tomosynthesis, bilateral CPT Procedure 77063
Codes to identify breast cancer diagnosis
Malignant neoplasm of nipple and areola of female breast ICD-9 Diagnosis 174.0
ICD-10 Diagnosis C50.01x
Malignant neoplasm of central portion of female breast ICD-9 Diagnosis 174.1
ICD-10 Diagnosis C50.11x
Malignant neoplasm of upper-inner quadrant of female breast ICD-9 Diagnosis 174.2
ICD-10 Diagnosis C50.21x
Malignant neoplasm of lower-inner quadrant of female breast ICD-9 Diagnosis 174.3
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Description Code Type Code
ICD-10 Diagnosis C50.31x
Malignant neoplasm of upper-outer quadrant of female breast ICD-9 Diagnosis 174.4
ICD-10 Diagnosis C50.41x
Malignant neoplasm of lower-outer quadrant of female breast ICD-9 Diagnosis 174.5
ICD-10 Diagnosis C50.51x
Malignant neoplasm of axillary tail of female breast ICD-9 Diagnosis 174.6
ICD-10 Diagnosis C50.61x
Malignant neoplasm of other specified sites of female breast ICD-9 Diagnosis 174.8
ICD-10 Diagnosis C50.81x
Malignant neoplasm of breast (female) unspecified site ICD-9 Diagnosis 174.9
ICD-10 Diagnosis C50.91x
Secondary malignant neoplasm of skin of breast ICD-9 Diagnosis 198.2x
ICD-10 Diagnosis C79.2x
Secondary malignant neoplasm of breast ICD-9 Diagnosis 198.81
ICD-10 Diagnosis C79.81
Carcinoma in situ of breast ICD-9 Diagnosis 233.0
ICD-10 Diagnosis D05.xx
Neoplasm of uncertain behavior of breast ICD-9 Diagnosis 238.3
ICD-10 Diagnosis D48.6x
Neoplasm of unspecified nature of breast ICD-9 Diagnosis 239.3
ICD-10 Diagnosis D49.3
Personal history of malignant neoplasm of breast ICD-9 Diagnosis V10.3
ICD-10 Diagnosis Z85.3
Codes to identify breast cancer sign or symptom
Lump or mass in breast ICD-9 Diagnosis 611.72
ICD-10 Diagnosis N63.xx
Mastodynia pain in breast ICD-9 Diagnosis 611.71
ICD-10 Diagnosis N64.4
Other signs and symptoms in breast Induration of breast Inversion of nipple Nipple 
discharge retraction of nipple
ICD-9 Diagnosis 611.79
ICD-10 Diagnosis N64.5x
Specified congenital anomalies of breast Accessory breast or nipple Congenital 
absent breast or nipple Supernumerary breast or nipple
ICD-9 Diagnosis 757.6
ICD-10 Diagnosis Q83.x
Codes to identify breast involvement
Secondary and unspecified malignant neoplasm of lymph nodes of axilla and upper 
limb Brachial Epitrochlear Infraclavicular Pectoral
ICD-9 Diagnosis 196.3
ICD-10 Diagnosis C77.3
Benign neoplasm of breast (female) connective tissue glandular tissue soft parts ICD-9 Diagnosis 217.x
ICD-10 Diagnosis D24.x
Benign mammary dysplasia ICD-9 Diagnosis 610.x
ICD-10 Diagnosis N60.x
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Description Code Type Code
Inflammatory disease of breast ICD-9 Diagnosis 611.0
ICD-10 Diagnosis N61.x
Hypertrophy of breast ICD-9 Diagnosis 611.1
ICD-10 Diagnosis N62
Fissure of nipple ICD-9 Diagnosis 611.2
ICD-10 Diagnosis N64.0
Fat necrosis of breast ICD-9 Diagnosis 611.3
ICD-10 Diagnosis N64.1
Atrophy of breast ICD-9 Diagnosis 611.4
ICD-10 Diagnosis N64.2
Galactocele ICD-9 Diagnosis 611.5
ICD-10 Diagnosis N64.89
Galactorrhea not associated with childbirth ICD-9 Diagnosis 611.6
ICD-10 Diagnosis N64.3
Other specified disorders of breast ICD-9 Diagnosis 611.8x
ICD-10 Diagnosis N64.8x
Unspecified breast disorder ICD-9 Diagnosis 611.9
ICD-10 Diagnosis N64.9
Nonspecific abnormal findings on radiological and other examination of breast - 
Includes: nonspecific abnormal findings of thermography ultrasound examination 
[echogram] x-ray examination
ICD-9 Diagnosis 793.8x
ICD-10 Diagnosis R92.8x
Family history of malignant neoplasm of breast ICD-9 Diagnosis V16.3
ICD-10 Diagnosis Z80.3
Codes to identify bilateral or unilateral mastectomy
Bilateral simple mastectomy, Bilateral complete mastectomy ICD-9 Procedure 85.42
ICD-10 Procedure 0HTV0ZZ
Bilateral extended simple mastectomy ICD-9 Procedure 85.44
ICD-10 Procedure 0HTV0ZZ
Bilateral radical mastectomy ICD-9 Procedure 85.46
ICD-10 Procedure 0HTV0ZZ
Bilateral extended radical mastectomy ICD-9 Procedure 85.48
ICD-10 Procedure 0HTV0ZZ
Unilateral simple mastectomy, Mastectomy: NOS complete ICD-9 Procedure 85.41
ICD-10 Procedure 0HTT0ZZ
0HTU0ZZ
Unilateral extended simple mastectomy, Extended simple mastectomy NOS, 
Modified radical mastectomy, Simple mastectomy with excision of regional lymph 
nodes
ICD-9 Procedure 85.43
ICD-10 Procedure 0HTU0ZZ
0HTU0ZZ
Unilateral radical mastectomy, Excision of breast, pectoral muscles, and regional 
lymph nodes [axillary, clavicular, supraclavicular], Radical mastectomy NOS
ICD-9 Procedure 85.45
ICD-10 Procedure 0HTU0ZZ
0HTU0ZZ
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Description Code Type Code
Unilateral extended radical mastectomy, Excision of breast, muscles, and lymph 
nodes [axillary, clavicular, supraclavicular, internal mammary, and mediastinal], 
Extended radical mastectomy NOS
ICD-9 Procedure 85.47
ICD-10 Procedure 0HTU0ZZ
0HTU0ZZ
Mastectomy, simple, complete CPT Procedure 19303
Mastectomy, subcutaneous CPT Procedure 19304
Mastectomy, radical, including pectoral muscles, axillary lymph nodes CPT Procedure 19305
Mastectomy, radical, including pectoral muscles, axillary and internal mammary 
lymph nodes (Urban type operation)
CPT Procedure 19306
Mastectomy, modified radical, including axillary lymph nodes, with or without 
pectoralis minor muscle, but excluding pectoralis major muscle
CPT Procedure 19307
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Figure 1. 
Flow Diagram for Sample Selection
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Table 1:
Demographic characteristics of study population, MarketScan, 2012–2016
Variable Percent distribution
(N=685,737)
Age in years
 50 to 54 37.39
 55 to 59 51.46
 60 to 64 11.15
Relationship to employer  
 Spouse of employee 38.73
 Employee 61.21
Region  
 Northeast 17.15
 Midwest 23.02
 South 43.01
 West 14.72
Metropolitan statistical area  
 Yes 83.66
 No 16.29
Insurance type  
 Fee-for-service plan 7.53
 Managed care-noncapitated plan 81.11
 CDHP/HDHP# 11.36
#CDHP/HDHP: Consumer directed health plan/High deductible health plan
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